Glycogen synthase kinase-3 (GSK3)

Regulation, actions, and diseases

Eleonore Beurel, Steven F. Grieco, Richard S Jope

Research output: Contribution to journalArticle

337 Citations (Scopus)

Abstract

Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.

Original languageEnglish
Pages (from-to)114-131
Number of pages18
JournalPharmacology and Therapeutics
Volume148
DOIs
StatePublished - 2015

Fingerprint

Glycogen Synthase Kinase 3
Protein Transport
Post Translational Protein Processing

Keywords

  • Alzheimer's disease
  • Depression
  • G protein-coupled receptors
  • Glycogen synthase kinase-3
  • Lithium
  • Neuroinflammation

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Glycogen synthase kinase-3 (GSK3) : Regulation, actions, and diseases. / Beurel, Eleonore; Grieco, Steven F.; Jope, Richard S.

In: Pharmacology and Therapeutics, Vol. 148, 2015, p. 114-131.

Research output: Contribution to journalArticle

@article{256b48c3f0f0422daf1dd9bb56315d41,
title = "Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases",
abstract = "Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.",
keywords = "Alzheimer's disease, Depression, G protein-coupled receptors, Glycogen synthase kinase-3, Lithium, Neuroinflammation",
author = "Eleonore Beurel and Grieco, {Steven F.} and Jope, {Richard S}",
year = "2015",
doi = "10.1016/j.pharmthera.2014.11.016",
language = "English",
volume = "148",
pages = "114--131",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Glycogen synthase kinase-3 (GSK3)

T2 - Regulation, actions, and diseases

AU - Beurel, Eleonore

AU - Grieco, Steven F.

AU - Jope, Richard S

PY - 2015

Y1 - 2015

N2 - Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.

AB - Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.

KW - Alzheimer's disease

KW - Depression

KW - G protein-coupled receptors

KW - Glycogen synthase kinase-3

KW - Lithium

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=84923265392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923265392&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2014.11.016

DO - 10.1016/j.pharmthera.2014.11.016

M3 - Article

VL - 148

SP - 114

EP - 131

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -